The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells

Severe COVID-19 is characterized by angiogenic features, such as intussusceptive angiogenesis, endothelialitis, and activation of procoagulant pathways. This pathological state can be ascribed to a direct SARS-CoV-2 infection of human lung ECs. Recently, we showed the capability of SARS-CoV-2 to infect ACE2-negative primary human lung microvascular endothelial cells (HL-mECs). This occurred through the interaction of an Arg-Gly-Asp (RGD) motif, endowed on the Spike protein at position 403–405, with αvβ3 integrin expressed on HL-mECs. HL-mEC infection promoted the remodeling of cells toward a pro-inflammatory and pro-angiogenic phenotype. The RGD motif is distinctive of SARS-CoV-2 Spike proteins up to the Omicron BA.1 subvariant. Suddenly, a dominant D405N mutation was expressed on the Spike of the most recently emerged Omicron BA.2, BA.4, and BA.5 subvariants. Here we demonstrate that the D405N mutation inhibits Omicron BA.5 infection of HL-mECs and their dysfunction because of the lack of Spike/integrins interaction. The key role of ECs in SARS-CoV-2 pathogenesis has been definitively proven. Evidence of mutations retrieving the capability of SARS-CoV-2 to infect HL-mECs highlights a new scenario for patients infected with the newly emerged SARS-CoV-2 Omicron subvariants, suggesting that they may display less severe disease manifestations than those observed with previous variants.

[1]  R. Podgornik,et al.  Impact of BA.1, BA.2, and BA.4/BA.5 Omicron Mutations on Therapeutic Monoclonal Antibodies , 2022, bioRxiv.

[2]  A. Caruso,et al.  Endothelial cells are major players in SARS-CoV-2-related acute respiratory distress syndrome , 2022, eBioMedicine.

[3]  C. Garlanda,et al.  Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 , 2022, Frontiers in Immunology.

[4]  S. Rong,et al.  Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate , 2022, Scientific Reports.

[5]  M. Karsdal,et al.  The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling , 2022, eBioMedicine.

[6]  Hossein Estiri,et al.  Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England , 2022, JAMA network open.

[7]  R. Gómez,et al.  Proteomic Analysis Identifies Molecular Players and Biological Processes Specific to SARS-CoV-2 Exposure in Endothelial Cells , 2022, International journal of molecular sciences.

[8]  D. Ueno,et al.  Senescent endothelial cells are predisposed to SARS-CoV-2 infection and subsequent endothelial dysfunction , 2022, Scientific Reports.

[9]  Qian Wang,et al.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.

[10]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[11]  Arvind H. Patel,et al.  The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein , 2022, bioRxiv.

[12]  D. Jonigk,et al.  Endothelialitis, Microischemia, and Intussusceptive Angiogenesis in COVID-19. , 2022, Cold Spring Harbor perspectives in medicine.

[13]  E. Belley‐Cote,et al.  Venous and arterial thrombosis in COVID-19: An updated narrative review , 2022, Journal of Infection and Public Health.

[14]  P. Chiodelli,et al.  SARS-CoV-2 Infects Human ACE2-Negative Endothelial Cells through an αvβ3 Integrin-Mediated Endocytosis Even in the Presence of Vaccine-Elicited Neutralizing Antibodies , 2022, Viruses.

[15]  P. Boor,et al.  INFLAMMATION AND VASCULAR REMODELING IN COVID-19 HEARTS , 2022, Journal of the American College of Cardiology.

[16]  D. Scheim A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody , 2022, International journal of molecular sciences.

[17]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[18]  W. Hanage,et al.  Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. , 2022, The New England journal of medicine.

[19]  L. Poon,et al.  SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.

[20]  N. Rahimi,et al.  Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells , 2022, Proceedings of the National Academy of Sciences.

[21]  Peng Sun,et al.  Cardiovascular Risk After SARS-CoV-2 Infection Is Mediated by IL18/IL18R1/HIF-1 Signaling Pathway Axis , 2022, Frontiers in Immunology.

[22]  I. Douglas,et al.  Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19 , 2021, JAMA network open.

[23]  D. Easton,et al.  Covid-19 Vaccine Effectiveness in New York State , 2021, The New England journal of medicine.

[24]  S. Hsu,et al.  Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2 , 2021, Nature Chemical Biology.

[25]  C. Clapp,et al.  The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling , 2021, bioRxiv.

[26]  Jinrong Fu,et al.  The signal pathways and treatment of cytokine storm in COVID-19 , 2021, Signal Transduction and Targeted Therapy.

[27]  L. Dölken,et al.  SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro , 2021, Frontiers in Cellular and Infection Microbiology.

[28]  F. Facchetti,et al.  SARS-CoV-2 Infection Remodels the Phenotype and Promotes Angiogenesis of Primary Human Lung Endothelial Cells , 2021, Microorganisms.

[29]  N. Fletcher,et al.  SARS-CoV-2 uses major endothelial integrin αvβ3 to cause vascular dysregulation in-vitro during COVID-19 , 2021, PloS one.

[30]  N. Banholzer,et al.  Estimating the effects of non-pharmaceutical interventions on the number of new infections with COVID-19 during the first epidemic wave , 2021, medRxiv.

[31]  A. Moreau,et al.  High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19 , 2021, Infectious Diseases Now.

[32]  J. Haas,et al.  Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells , 2021, Circulation.

[33]  K. Schroder,et al.  Endothelial cells are not productively infected by SARS‐CoV‐2 , 2021, Clinical & translational immunology.

[34]  V. Ferrer,et al.  Endothelial cells and SARS-CoV-2: An intimate relationship , 2020, Vascular Pharmacology.

[35]  T. Hobman,et al.  Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19 , 2020, Viruses.

[36]  L. Rénia,et al.  Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation , 2020, medRxiv.

[37]  E. Mackow,et al.  Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses , 2020, bioRxiv.

[38]  P. Sorger,et al.  Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques , 2020, Cell.

[39]  J. P. de Rivero Vaccari,et al.  The Inflammasome in Times of COVID-19 , 2020, Frontiers in Immunology.

[40]  P. Venkatesan The changing demographics of COVID-19 , 2020, The Lancet Respiratory Medicine.

[41]  G. Curley,et al.  A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets? , 2020, Drug Discovery Today.

[42]  M. Ciccozzi,et al.  A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual , 2020, Journal of translational medicine.

[43]  L. Alberghina,et al.  Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro” , 2020, Journal of medical virology.

[44]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[45]  P. Anyfanti,et al.  Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses , 2020, Current Hypertension Reports.

[46]  P. Libby,et al.  COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.

[47]  C. Cheung,et al.  Vascular underpinning of COVID-19 , 2020, Open Biology.

[48]  William E. Arter,et al.  Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? , 2020, Clinical medicine.

[49]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[50]  C. Peano,et al.  Macropahge expression and prognostic significance of the long pentraxin PTX3 in COVID-19 , 2020, medRxiv.

[51]  Duc-Huy T. Nguyen,et al.  A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids , 2020, Cell Stem Cell.

[52]  F. Potus,et al.  Novel insights on the pulmonary vascular consequences of COVID-19 , 2020, American journal of physiology. Lung cellular and molecular physiology.

[53]  É. Azoulay,et al.  The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection , 2020, Critical Care.

[54]  Guohui Wan,et al.  New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection , 2020, Frontiers in Pharmacology.

[55]  A. Huisman,et al.  Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS‐CoV‐2 , 2020, International journal of laboratory hematology.

[56]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[57]  M. Hollinshead,et al.  Electron microscopic investigations in COVID-19: not all crowns are coronas , 2020, Kidney International.

[58]  P. Carmeliet,et al.  COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.

[59]  A. Osterhaus,et al.  Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19) , 2020, The Journal of pathology.

[60]  J. Bartholomew,et al.  Coagulopathy in COVID-19. , 2020, Cleveland Clinic journal of medicine.

[61]  D. Alsteens,et al.  Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans. , 2020, Annual review of virology.

[62]  John T Brooks,et al.  Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic , 2020, Emerging infectious diseases.

[63]  Sara E. Miller,et al.  Electron microscopy of SARS-CoV-2: a challenging task , 2020, The Lancet.

[64]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[65]  Niema Moshiri,et al.  ViralMSA: Massively scalable reference-guided multiple sequence alignment of viral genomes , 2020, bioRxiv.

[66]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[67]  K. Yuen,et al.  Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.

[68]  Ruiyun Li,et al.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) , 2020, Science.

[69]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[70]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[71]  Olga Chernomor,et al.  IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.

[72]  Heng Li,et al.  Minimap2: pairwise alignment for nucleotide sequences , 2017, Bioinform..

[73]  Trevor Bedford,et al.  Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.

[74]  Richard A Neher,et al.  TreeTime: Maximum-likelihood phylodynamic analysis , 2017, bioRxiv.

[75]  Yuelong Shu,et al.  GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[76]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.

[77]  P. Sagulenko Maximum likelihood phylodynamic analysis , 2017 .

[78]  V. Frémeaux-Bacchi,et al.  Endothelial cells: source, barrier, and target of defensive mediators , 2016, Immunological reviews.

[79]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[80]  T. Stehle,et al.  Glycan Engagement by Viruses: Receptor Switches and Specificity. , 2014, Annual review of virology.

[81]  M. Slevin,et al.  HIV-1 Matrix Protein p17 Promotes Lymphangiogenesis and Activates the Endothelin-1/Endothelin B Receptor Axis , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[82]  M. Rusnati,et al.  Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. , 2009, Current pharmaceutical design.

[83]  H Lortat-Jacob,et al.  Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat* , 2001, The Journal of Biological Chemistry.